Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jan 25:24:52-56.
doi: 10.12659/AOT.911712.

Good Results with Individually Adapted Long-Term Immunosuppression Following Alemtuzumab Versus ATG Induction Therapy in Combined Kidney-Pancreas Transplantation: A Single-Center Report

Claudia Bösmüller  1 , Franka Messner  1 , Christian Margreiter  1 , Robert Öllinger  2 , Manuel Maglione  1 , Rupert Oberhuber  1 , Stefan Scheidl  1 , Hannes Neuwirt  3 , Dietmar Öfner  1 , Raimund Margreiter  1 , Stefan Schneeberger  1
Affiliations
Randomized Controlled Trial

Good Results with Individually Adapted Long-Term Immunosuppression Following Alemtuzumab Versus ATG Induction Therapy in Combined Kidney-Pancreas Transplantation: A Single-Center Report

Claudia Bösmüller et al. Ann Transplant. .

Abstract

Retrospective analysis of the long-term results of a randomized controlled trial comparing alemtuzumab (ALEM) and antithymocyte globulin (ATG) as induction therapy in simultaneous pancreas-kidney transplantation (SPK) to address individualized long-term immunosuppression.

Between 2006 and 2010 a total of 30 SPKs were randomized to treatment with ALEM plus tacrolimus (TAC) monotherapy (Group A, n=14) versus ATG induction plus TAC, mycophenolate mofetil (MMF) and steroids (Group B, n=16), followed by individualized long-term immunosuppression. We here present the long-term results for graft survival, graft function, and major complications.

The 9-year patient survival rates in Groups A and Group B were 92.9% and 86.7% respectively; pancreas graft survival was 75.0% and 65.0% respectively; renal graft survival was 83.1% and 93.8% respectively. Long-term graft function was excellent with a creatinine of 1.5 mg/dL and 1.4 mg/dL, fasting glycemia of 104 mg/dL and 102 mg/dL, hemoglobin (Hb) A1c of 5.4 g% and 5.6 g% in Group A and Group B, respectively. Major complications were comparable in both groups.

Good long-term results for patient, pancreas graft and kidney graft survival were achieved in both groups with individually adapted maintenance immunosuppression. ALEM is a valid induction therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

None.

References

    1. Kopp WH, Verhagen MJ, Blok JJ, et al. Thirty years of pancreas transplantation at Leiden University Medical Center: long-term follow-up in a large Eurotransplant center. Transplantation. 2015;99(9):e145–51. - PubMed
    1. Öllinger R, Margreiter C, Bösmüller C, et al. Evolution of pancreas transplantation: Long-term results and perspectives from a high-volume center. Ann Surg. 2012;256(5):780–86. - PubMed
    1. Niederhaus SV, Kaufman DB, Odorico JS. Induction therapy in pancreas transplantation. Transpl Int. 2013;26(7):704–14. - PubMed
    1. Tai DS, Hong J, Busuttil RW, Lipshutz GS. Low rates of short- and long-term graft loss after kidney-pancreas transplant from a single center. JAMA Surg. 2013;148(4):368–73. - PubMed
    1. Dholakia S, Oskrochi Y, Easton G, Papalois V. Advances in pancreas transplantation. J R Soc Med. 2016;109(4):141–46. - PMC - PubMed